ArticleScientific reports2020
Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.Hepatology (Baltimore, Md.) · 2022Pooled it
- Differential aging trends among candidates for liver transplant with and without HCC.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2025Article
- Article
- Geographic diversity of human liver cancers mirrors global social inequalities.Frontiers in oncology · 2025Review
- A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population.Cancer medicine · 2024Article
- A Longitudinal Analysis of Mortality Related to Chronic Viral Hepatitis and Hepatocellular Carcinoma in the United States.Viruses · 2024Article
- Single-Cell RNA Sequencing Identifies Crucial Genes Influencing the Polarization of Tumor-Associated Macrophages in Liver Cancer.International journal of genomics · 2024Article
- Trends of primary liver cancer incidence and mortality in the United States: A population-based study over the last four decades.PloS one · 2024Article
- C18ORF54 promotes immune infiltration and poor prognosis as a potential biomarker for hepatocellular carcinoma.American journal of translational research · 2023Article
- Hepatitis C virus: A critical approach to who really needs treatment.World journal of hepatology · 2022Review
- The Elevated Circ_0067835 Could Accelerate Cell Proliferation and Metastasis via miR-1236-3p/Twist2 Axis in Hepatocellular Carcinoma.BioMed research international · 2022Article
- Hepatocellular carcinoma surveillance: current practice and future directions.Hepatoma research · 2022Article
- Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance.Frontiers in surgery · 2022Article
- Frontiers of therapy for hepatocellular carcinoma.Abdominal radiology (New York) · 2021Review
- The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma.Cancers · 2021Review
- Cellular based treatment modalities for unresectable hepatocellular carcinoma.World journal of clinical oncology · 2021Review
- Spatial heterogeneity of hepatic fibrosis in primary sclerosing cholangitis vs. viral hepatitis assessed by MR elastography.Scientific reports · 2021Observational
- Article
- m6A Modification-MediatedFrontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is the main cause of hepatocellular carcinoma (HCC) in the United States (US) and an increasingly common cause of HCC in China. We aimed to evaluate the incidence and risk factors of HCC in HCV patients in the US and China. 795 HCV RNA + patients without HCC from University of Michigan Health System (UMHS) in the US and 854 from Peking University Health Sciences Center (PUHSC) in China were prospectively followed for a median of 3.2 and 4.0 years, respectively. 45.4% UMHS and 16.2% PUHSC patients had cirrhosis. 57.6% UMHS and 52.0% PUHSC patients achieved SVR. 45 UMHS and 13 PUHSC patients developed HCC. Cumulative incidence of HCC at 5 years was 7.6% in UMHS and 1.8% in PUHSC cohort (P < 0.001). Ten patients not diagnosed with cirrhosis at enrollment but median APRI ≥ 2.0 developed HCC. Multivariate analysis showed age, gender, cirrhosis and APRI were predictors of HCC while study site and SVR were not. In this study of HCV patients, HCC incidence in the PUHSC cohort was lower than in the UMHS cohort, due to lower proportion of PUHSC patients with cirrhosis. APRI can identify risk of HCC among patients not diagnosed to have cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.